"Elafin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A secretory proteinase inhibitory protein that was initially purified from human SKIN. It is found in a variety mucosal secretions and is present at high levels in SPUTUM. Elafin may play a role in the innate immunity (IMMUNITY, INNATE) response of the LUNG.
| Descriptor ID |
D053492
|
| MeSH Number(s) |
D12.644.822.437 D12.776.645.437
|
| Concept/Terms |
Elafin- Elafin
- Skin-Derived Antileukoproteinase
- Antileukoproteinase, Skin-Derived
- Skin Derived Antileukoproteinase
- Protease Inhibitor 3, Skin-derived
- Protease Inhibitor 3, Skin derived
- Protease Inhibitor WAP3
- Inhibitor WAP3, Protease
- Peptidase Inhibitor 3, Skin-derived
- Peptidase Inhibitor 3, Skin derived
|
Below are MeSH descriptors whose meaning is more general than "Elafin".
Below are MeSH descriptors whose meaning is more specific than "Elafin".
This graph shows the total number of publications written about "Elafin" by people in this website by year, and whether "Elafin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2007 | 1 | 0 | 1 |
| 2010 | 2 | 0 | 2 |
| 2012 | 0 | 1 | 1 |
| 2013 | 1 | 0 | 1 |
| 2014 | 3 | 0 | 3 |
| 2017 | 0 | 1 | 1 |
| 2021 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Elafin" by people in Profiles.
-
Elafin promotes tumour metastasis and attenuates the anti-metastatic effects of erlotinib via binding to EGFR in hepatocellular carcinoma. J Exp Clin Cancer Res. 2021 Mar 26; 40(1):113.
-
Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab. JAMA Oncol. 2017 Apr 01; 3(4):509-515.
-
The serine protease inhibitor elafin maintains normal growth control by opposing the mitogenic effects of neutrophil elastase. Oncogene. 2015 Jul; 34(27):3556-67.
-
Elafin drives poor outcome in high-grade serous ovarian cancers and basal-like breast tumors. Oncogene. 2015 Jan 15; 34(3):373-83.
-
Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence. Breast Cancer Res. 2014; 16(6):3417.
-
Elafin, an inhibitor of elastase, is a prognostic indicator in breast cancer. Breast Cancer Res. 2013 Jan 15; 15(1):R3.
-
Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a Blood and Marrow Transplant Clinical Trials Network study. Blood. 2012 Apr 19; 119(16):3854-60.
-
The neutrophil elastase inhibitor elafin triggers rb-mediated growth arrest and caspase-dependent apoptosis in breast cancer. Cancer Res. 2010 Sep 15; 70(18):7125-36.
-
Elafin is a biomarker of graft-versus-host disease of the skin. Sci Transl Med. 2010 Jan 06; 2(13):13ra2.
-
Differential regulation of elafin in normal and tumor-derived mammary epithelial cells is mediated by CCAAT/enhancer binding protein beta. Cancer Res. 2007 Dec 01; 67(23):11272-83.